Reported Late Wednesday March 08, ProMIS Neurosciences Announces FY22 Financial Results And Recent Highlights; Cash And Cash Equivalents Were $5.9M As Of December 31, 2022 Vs $16.9M YoY
Completed all preclinical studies and manufacturing to support PMN310 IND submission to U.S. Food and Drug Administration
Preclinical data that further characterize ongoing programs, including PMN310, to be presented